Hepion Pharmaceuticals stock (US4268971032): delisting, strategy and what investors should know now

Hepion Pharmaceuticals has moved further into the spotlight of speculative biotech trading after its shares were delisted from Nasdaq in late 2024 and transitioned to the over?the?counter market, while the company continues to focus on developing its lead drug candidate rencofilstat for liver disease, according to a company update published on 11/14/2024 on the investor relations website and related market notices from late 2024 Hepion investor update as of 11/14/2024.

As of: 05/21/2026

By the editorial team – specialized in equity coverage.

Hepion Pharmaceuticals: core business model

Hepion Pharmaceuticals is a clinical?stage biotechnology company focused on developing treatments for serious liver diseases, with an emphasis on nonalcoholic steatohepatitis (NASH) and other forms of liver fibrosis, as outlined in its corporate profile on the company website Hepion website overview as of 03/10/2025.

The company’s strategy centers on rencofilstat, an oral inhibitor of cyclophilin, a protein family involved in cellular stress and fibrotic processes, which Hepion believes could address multiple liver disease pathways according to its pipeline descriptions and scientific presentations shared through its investor materials in 2024 Hepion pipeline description as of 09/30/2024.

As a clinical?stage biotech, Hepion currently generates minimal or no product revenue and largely funds operations through equity financing and other capital?raising measures, which the company detailed in its 2023 annual report filed in early 2024, including disclosure of operating losses and cash burn trends for that reporting year Hepion Form 10?K as of 03/28/2024.

The business model is highly dependent on successful clinical development, regulatory approval and eventual commercialization or partnering of its drug candidates, meaning that setbacks in trials, changes in regulatory expectations, or delays in funding can have a substantial impact on the company’s prospects and on the trading dynamics of Hepion shares.

Main revenue and product drivers for Hepion Pharmaceuticals

The main potential revenue driver for Hepion is rencofilstat, formerly known as CRV431, which is being investigated for the treatment of nonalcoholic steatohepatitis and potentially other liver conditions, according to clinical trial summaries and presentations linked from the company’s pipeline updates during 2024 Hepion news releases as of 11/14/2024.

Hepion has reported data from earlier?stage clinical studies suggesting that rencofilstat may impact key biomarkers associated with liver fibrosis, though the company has also indicated that larger, well?controlled trials will be necessary to confirm efficacy and support potential regulatory submissions, as outlined in its 2024 clinical program updates published in mid?2024 alongside conference presentations Hepion presentations overview as of 06/15/2024.

Because Hepion is still pre?commercial and has historically reported net losses, future revenue could also come from licensing agreements, strategic collaborations or milestone payments if larger pharmaceutical partners choose to co?develop or commercialize rencofilstat in major markets such as the United States, Europe or Asia, a path that management discussed as a strategic option in its 2023 annual report and subsequent shareholder communications released in 2024.

In addition to rencofilstat, Hepion continues to explore potential applications of its cyclophilin inhibition platform in other indications, although these programs are at earlier stages and contribute more to the company’s long?term optionality than to near?term revenue expectations, which remains a typical profile for small biotech names on the OTC and Nasdaq markets.

Conclusion

Hepion Pharmaceuticals represents a high?risk biotech story centered on a single main asset, rencofilstat, with ongoing liver disease trials and a clear need for additional capital and positive data to advance toward any commercial stage, as discussed in its 2023 annual report and 2024 investor updates Hepion filings overview as of 03/28/2024.

The move from a Nasdaq listing to trading on the OTC market underscores the volatility and listing?standard challenges that smaller clinical?stage biotechs can face, but it does not change the underlying scientific ambition to develop new therapies for liver disease, a significant unmet medical need area in the United States and globally.

For US retail investors following the stock, key variables to monitor include future clinical readouts for rencofilstat, management’s ability to secure funding or partnerships on reasonable terms, and any additional communication from the company on its strategic direction; all of these factors can influence sentiment and liquidity in Hepion shares, without guaranteeing any specific outcome.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.